TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

Wed, Aug 31, 2022 08:00 CET

Viken, Sweden – 31^st August 2022 – TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed’s ILB® neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors. TikoMed believes this approach to enhancing the body’s self-repair and regeneration capabilities has the potential to transform current cell and gene therapy paradigms.

“These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects that play a key role in controlling glutamate toxicity, normalising tissue bioenergetics, and resolving inflammation to improve tissue function. ILB®’s unique mechanism of action supports the potential to treat various acute and chronic neurodegenerative disease, including sTBI and ALS.” said Ann Logan, Scientific Director at Axolotl Consulting and, Professor of Regenerative Medicine at the University of Warwick

In summary, the studies provided evidence that ILB® has a profound therapeutic effect on molecular and cellular dysfunctions causing neurodegenerative diseases. Gene expression analysis demonstrated substantial similarities in the functional dysregulation induced by severe traumatic brain injury (sTBI) and various human neurodegenerative conditions including ALS. Changes in gene expression following ILB® treatment supported a cascading beneficial effect of ILB® on growth factor activation resulting in the observed therapeutic effect. The transcriptional signature after ILB® treatment is relevant to cell survival, inflammation, glutamate signalling, metabolism and synaptogenesis, and is consistent with the activation of neuroprotective growth factors. The ability of ILB® to elevate circulating levels of heparin-binding growth factors in animal models and humans also supports its neuroprotective and regenerative effects in vivo.

“ILB® is currently being in development both as a therapeutic and as an enabling technology for advanced therapies, and this peer-reviewed research indicates even wider potential. We have initiated development programs for Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation and will now consider broader use across a wider range of diseases,” said Anders Kristensson, CEO of TikoMed.

Contact: info@tikomed.com or +46 42 23 84 40

Media:

International: Richard Hayhurst richard@rhapr.eu or +44 7711 821527

Nordics: Ola Bjorkman ola.bjorkman@letemknow.se or +46 70 245 7497

Tikomed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi modal mechanism of action, Tikomed's platform rebalances the body’s inflammatory and immune response to acute and chronic inflammation. Currently applied in neurodegeneration and advanced therapies, with an initial focus on ALS, TBI and islet cell transplantation, Tikomed’s highly scalable proprietary technology aims to provide safe, qualitative and affordable medicine to as many patients as possible across the globe. Tikomed is privately-owned and based in Viken, Sweden.

Tags:

ALS regeneration Neurodegeneration Tikomed ILB Amyotrophic lateral sclerosis Neuroinflammation